
Real world evidence (RWE) provides a large and growing source of insights into drug uptake and safety. It is increasingly used in pricing and reimbursement negotiations and to support post-approval label expansions. In oncology where conditions are increasingly defined by genotype, there is a greater opportunity for RWE to facilitate regulatory approvals.
As more payers and HTA agencies turn to real world data to compare the effectiveness of various treatment effects, we need to assess how to use RWE to determine whether there is an unmet need that a new therapy can fulfill. In this final Winter Weekend Blog, we bring you an eBook that explores the full potential of real world data for Research and Development.
This e-book will: